Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...